D&D Pharmatech is a global biotech company that specializes in developing therapeutics for healthy aging. With a focus on improving quality of life and promoting healthy aging, D&D funds the development of revolutionary medicines through disease-specific subsidiary companies. The company's product pipeline covers a range of indications, including neurodegenerative and fibrotic diseases.

D&D Pharmatech also emphasizes the application of big data in CNS drug research and diagnostics. D&D operates through multiple partnerships and owns subsidiaries that focus on specific therapeutic areas. These subsidiaries include Neuraly, Precision Molecular, Valted Seq, Theraly, and P4 Microbiome.

Each subsidiary is dedicated to advancing research and developing innovative treatments for specific diseases. For example, Neuraly is focused on translating scientific discoveries in neurology into new drugs for Parkinson’s disease, Alzheimer’s disease, and other neurodegenerative disorders. Precision Molecular develops imaging biomarkers and theranostics for various cancers and neurodegenerative diseases.

Valted Seq focuses on discovering neurodegenerative pathways and biomarkers to inform the development of new therapeutics and diagnostics. Theraly is dedicated to developing innovative treatments for fibrotic diseases. And P4 Microbiome focuses on developing microbiome-focused therapies for unmet medical needs.

Overall, D&D Pharmatech's unique corporate structure and research focus make it a leader in the biotech industry, aiming to transform lives and advance healthcare through groundbreaking medicines